The NSABP B‐52 trial evaluated pathologic complete response rates in patients with hormone receptor and HER2-positive breast cancer treated with neoadjuvant therapy of docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) with or without concurrent estrogen deprivation therapy. The gene discussed is NR4A1; the disease is breast carcinoma.